Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)

NCT03795311 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: FOLFIRINOX Bevacizumab

Sponsor

Centre Georges Francois Leclerc